PAPER Mondal A, Bose D, Saha P, Sarkar S, Seth R, Kimono D, Albadrani M, Nagarkatti M, Nagarkatti P, Chatterjee S
SEARCH RESULTS
1477 RESULTS
"Brain's Resilience and Intelligence Networks (B.R.A.I.N.)" Seminar Series: Meditation as a mental training to promote healthy aging and prevent neurodegenerative diseases: the Medit-Ageing model
CONFERENCE 2020-07-16 00:00:00-2020-07-16 00:00:00 Online Meeting 16 July 2020 Organizer: Michael Ewers, Ph.D., Ludwig Maximilian University, Munich & German Center for Neurodegenerative Diseases (DZNE) Munich. Speaker: Gaël Chételat, PhD & Antoine Lutz, PhD, INSERM, France Meeting time: 11 AM E
QALSODY™
THERAPEUTICS Biogen IONIS Pharmaceuticals Tofersen BIIB067 Ionis-SOD1Rx ASO1 DNA/RNA-based Other In January 2016, Biogen and Ionis began a Phase 1/2 safety trial in SOD1-ALS. The study enrolled 84 people who received single or multiple ascending doses by intrathecal i
Marcio Silva
Brazil
Susanne Fabre
Stockholm, Sweden
PAPER Verkhratsky A, Zorec R
Large-Scale Proteomics Highlights Glial Role in Neurodegeneration.
Cell Metab. 2020 Jul 7;32(1):11-12. PubMed: 32640242PAPER Nogueras-Ortiz CJ, Mahairaki V, Delgado-Peraza F, Das D, Avgerinos K, Eren E, Hentschel M, Goetzl EJ, Mattson MP, Kapogiannis D
Astrocyte- and Neuron-Derived Extracellular Vesicles from Alzheimer's Disease Patients Effect Complement-Mediated Neurotoxicity.
Cells. 2020 Jul 4;9(7) PubMed: 32635578PAPER Hernández-Rodríguez M, Arciniega-Martínez IM, García-Marín ID, Correa-Basurto J, Rosales-Hernández MC
Chronic Administration of Scopolamine Increased GSK3βP9, Beta Secretase, Amyloid Beta, and Oxidative Stress in the Hippocampus of Wistar Rats.
Mol Neurobiol. 2020 Sep;57(9):3979-3988. Epub 2020 Jul 7 PubMed: 32638218PAPER Henríquez G, Mendez L, Schmid AN, Guerrero ED, Collins SA, Castañeda E, Narayan M
Testing Amyloid Cross-Toxicity in the Vertebrate Brain.
ACS Omega. 2020 Jun 30;5(25):15586-15591. Epub 2020 Jun 15 PubMed: 32637834PAPER Peters ST, Fahrenkopf A, Choquette JM, Vermilyea SC, Lee MK, Vossel K
Ablating Tau Reduces Hyperexcitability and Moderates Electroencephalographic Slowing in Transgenic Mice Expressing A53T Human α-Synuclein.
Front Neurol. 2020;11:563. Epub 2020 Jun 19 PubMed: 32636798PAPER Crotty GF, Schwarzschild MA
Chasing Protection in Parkinson's Disease: Does Exercise Reduce Risk and Progression?
Front Aging Neurosci. 2020;12:186. Epub 2020 Jun 19 PubMed: 32636740PAPER Schepici G, Silvestro S, Bramanti P, Mazzon E
Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson's Disease.
Int J Mol Sci. 2020 Jul 4;21(13) PubMed: 32635541PAPER Hardiman O, van den Berg LH
The Beginning of Genomic Therapies for ALS.
N Engl J Med. 2020 Jul 9;383(2):180-181. PubMed: 32640137PAPER Mueller C, Berry JD, McKenna-Yasek DM, Gernoux G, Owegi MA, Pothier LM, Douthwright CL, Gelevski D, Luppino SD, Blackwood M, Wightman NS, Oakley DH, Frosch MP, Flotte TR, Cudkowicz ME, Brown RH Jr
SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS.
N Engl J Med. 2020 Jul 9;383(2):151-158. PubMed: 32640133PAPER Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, Genge A, Glass J, Ladha S, Ludolph AL, Maragakis NJ, McDermott CJ, Pestronk A, Ravits J, Salachas F, Trudell R, Van Damme P, Zinman L, Bennett CF, Lane R, Sandrock A, Runz H, Graham D, Houshyar H, McCampbell A, Nestorov I, Chang I, McNeill M, Fanning L, Fradette S, Ferguson TA
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
N Engl J Med. 2020 Jul 9;383(2):109-119. PubMed: 32640130Current Filters
- Date Range : Jun 2020 to Jul 2020 x